Shares of Vitamin Shoppe, Inc (NYSE:VSI) have earned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $12.57.
VSI has been the subject of several research reports. Bank of America Corporation reaffirmed an “underperform” rating and set a $5.00 price objective (down previously from $5.50) on shares of Vitamin Shoppe in a research note on Wednesday, August 23rd. Zacks Investment Research cut shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. ValuEngine cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Barclays PLC reaffirmed an “equal weight” rating and set a $13.00 price objective (down previously from $24.00) on shares of Vitamin Shoppe in a research note on Sunday, May 14th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $7.00 price objective (down previously from $14.00) on shares of Vitamin Shoppe in a research note on Thursday, August 10th.
Vitamin Shoppe (NYSE VSI) traded down 5.26% during trading on Tuesday, hitting $5.40. The stock had a trading volume of 486,883 shares. The stock’s market cap is $128.47 million. Vitamin Shoppe has a 12 month low of $4.95 and a 12 month high of $28.41. The firm has a 50 day moving average of $7.43 and a 200-day moving average of $13.71.
Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Wednesday, August 9th. The specialty retailer reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by $0.16. Vitamin Shoppe had a negative net margin of 11.98% and a positive return on equity of 8.33%. The business had revenue of $304.84 million for the quarter, compared to analysts’ expectations of $314.74 million. During the same period in the prior year, the company posted $0.55 EPS. The firm’s revenue was down 8.4% on a year-over-year basis. Equities analysts predict that Vitamin Shoppe will post $0.79 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Vitamin Shoppe, Inc (VSI) Receives $12.57 Consensus Price Target from Analysts” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/09/10/vitamin-shoppe-inc-vsi-receives-12-57-consensus-price-target-from-analysts.html.
In other Vitamin Shoppe news, Director John D. Bowlin bought 40,000 shares of Vitamin Shoppe stock in a transaction on Friday, August 25th. The shares were bought at an average cost of $5.50 per share, for a total transaction of $220,000.00. Following the acquisition, the director now directly owns 56,028 shares in the company, valued at $308,154. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in VSI. BNP Paribas Arbitrage SA raised its holdings in shares of Vitamin Shoppe by 2.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock valued at $108,000 after purchasing an additional 192 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of Vitamin Shoppe by 18.1% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,410 shares of the specialty retailer’s stock valued at $110,000 after purchasing an additional 1,440 shares in the last quarter. Mason Street Advisors LLC raised its holdings in shares of Vitamin Shoppe by 7.0% in the 1st quarter. Mason Street Advisors LLC now owns 5,569 shares of the specialty retailer’s stock valued at $112,000 after purchasing an additional 366 shares in the last quarter. Wolverine Trading LLC acquired a new stake in shares of Vitamin Shoppe in the 2nd quarter valued at $131,000. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Vitamin Shoppe by 17,041.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock valued at $140,000 after purchasing an additional 11,929 shares in the last quarter. Institutional investors and hedge funds own 96.86% of the company’s stock.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.